Object. The aim of this study was to examine tumor volume as a prognostic factor for patients with brain metastases treated with Gamma Knife surgery (GKS).
©AANS, 2013
S tereotactic radiosurgery (SRS) has become a common modality for the treatment of patients with brain metastases. 16 It has better local control than whole brain radiation therapy (WBRT) and is as effective as surgery. 9 Withholding WBRT upfront and giving SRS alone for patients with limited numbers of brain metastases (≤ 4) has been shown not to be detrimental to survival, and has therefore become an acceptable treatment approach. 2 This approach spares or at least delays the neurocognitive effects and other acute toxicities (alopecia, serous otitis media, and hearing loss) associated with WBRT. With the use of MRI surveillance, distant brain failure can be monitored closely and appropriately treated with salvage SRS or WBRT.
There is no consensus on what the optimal maximum number of targets treated with SRS might be. The general convention is that patients with more than 3-4 lesions may benefit from WBRT because of the high risk of distant brain failure and because tumor recurrence can lead to neurological decline that could be worse than the neurocognitive effects associated with WBRT. 12 Others believe that impairment in neurocognition can be avoided by withholding upfront WBRT and using WBRT for salvage treatment. 5 Current guidelines and prognostic scales, such as the Diagnosis-Specific Graded Prognostic Assessment (DS-GPA), 15 take into consideration the number of brain lesions but not the tumor volume. Emerging data suggest that tumor volume may be an important predictor of disease burden and outcome. 4, 11 Tumor volume as a predictor of survival and local control in patients with brain metastases treated with Gamma Knife surgery Abbreviations used in this paper: DS-GPA = Diagnosis-Specific Graded Prognostic Assessment; GKS = Gamma Knife surgery; HR = hazard ratio; KPS = Karnofsky Performance Scale; NSCLC = non-small cell lung carcinoma; RPA = recursive partitioning analysis; RTOG = Radiation Therapy Oncology Group; SRS = stereotactic radiosurgery; WBRT = whole brain radiation therapy.
Because there are limited published data examining tumor volume, we have conducted a review of our institution's experience analyzing patients who were initially treated with Gamma Knife surgery (GKS) alone. The objective of this study was to determine if the number of metastatic lesions and/or tumor volume would be predictive of outcome.
Methods

Patient Population and Selection Criteria
From December 2006 to August 2012, data from pa tients with brain metastases treated with GKS at William Beaumont Hospital were entered prospectively into a research database. Institutional guidelines for patient selection for GKS included an anticipated life expectancy at the time of treatment > 3 months, a maximum dimension of a single lesion ≤ 4 cm, and typically a Karnofsky Performance Scale (KPS) score ≥ 70; however, a limited number of patients with a KPS score < 70 were treated. Patients with 1-4 brain metastases were mainly selected, but patients with more than 4 lesions were also treated. All patients with more than 4 lesions were counseled and offered WBRT. Institutional policy was for the prescheduling diagnostic MRI to have been completed within 14 days of the actual GKS treatment. Sometimes, patients with 1-4 lesions identified initially at the time of radiosurgery scheduling were found to have additional lesions on the day of treatment, possibly related to the planning MRI slice thickness of 1 mm, physician scrutiny on the day of treatment, and/or natural disease progression.
Inclusion criteria for this study included patients who were treated initially with GKS alone. Patients who received WBRT or surgery as primary treatment for their brain metastases were excluded. After approval from the William Beaumont Hospital Human Investigation Committee, a total of 250 patients met the criteria and were queried from the database. Basic characteristics, which were entered prospectively at the time of GKS treatment, were obtained from the database. Outcomes and missing data were obtained retrospectively from patients' charts.
Radiosurgical Technique and Follow-Up
All patients were treated with the Leksell Gamma Knife model 4C (Elekta), which became operational at Beaumont Hospital in December 2006. After placement of the Leksell stereotactic head frame, patients underwent a noncontrast-enhanced CT scan and contrast-enhanced MRI. The tumor or tumors were contoured by the radiation oncologist and the neurosurgeon. The prescription dose was selected at the discretion of the treating radiation oncologist and neurosurgeon, taking into consideration the tumor size, shape, and location. Per institutional policy, the Radiation Therapy Oncology Group (RTOG) dosing guidelines 14 were generally used for dose selection, but at physician discretion. Per the guidelines, recommended dosing was 21-24 Gy for lesions ≤ 2 cm, 18 Gy for lesions 2-3 cm, and 15 Gy for lesions > 3 cm. Doses were typically prescribed to the 50% isodose volume with the median marginal dose being 18 Gy (10-24 Gy). Tumor volumes were obtained using the dose-volume histogram function from the Leksell GammaPlan planning software and entered prospectively into our database at the time of treatment.
Patients were typically followed-up 2 weeks and then 6 weeks after GKS and then every 3 months. Contrastenhanced MRI was generally performed 6 weeks after GKS and then every 3 months. Salvage therapies for local failure were employed when evidence of disease progression was found on MRI, MRI with spectroscopy and/or perfusion, or tumor biopsy. Recurrent cases were routinely discussed at our multidisciplinary CNS conference for consensus agreement. Surgery was typically used in patients with neurological symptoms caused by the enlarging recurrent tumor, large tumors that would not likely be well controlled with WBRT or GKS alone, or in cases in which surgical intervention was believed necessary for confirmation of tumor or necrosis. Whole brain radiation therapy and repeat GKS were also used based on physician discretion, considering tumor size and volume, number of lesions, KPS score, and patient willingness to undergo salvage WBRT. Chemotherapy was not used as salvage treatment for recurrence. Treatment for brain failure elsewhere included repeat GKS and WBRT, considering the factors described immediately above.
Statistical Analysis
Overall survival was calculated from the date of GKS. The DS-GPA score was determined using the updated published index, which takes into account histology. 15 Median survival of the RTOG recursive partitioning analysis (RPA) classes and the DS-GPA classes were compared using the log-rank test. Univariate and multivariate analyses were performed using the Cox regression model. A p value ≤ 0.05 was considered statistically significant. Linear regression analysis was used and the Pearson correlation coefficient was calculated to assess if the number of brain lesions was associated with total tumor volume. The estimated hazard ratios (HRs) and 95% CIs are reported. Statistical analyses were performed using SPSS (version 20, IBM).
Results
A total of 250 patients with 548 brain metastases fit the study criteria. Patient and treatment characteristics are given in Table 1 . The median follow-up was 7.0 months for all patients and 17.5 months for living patients.
Patient Survival
The median survival of the entire cohort was 7.1 months. The median survival for RTOG RPA Class 1, 2, and 3 was 20.2, 7.6, and 2.0 months, respectively (p < 0.001). The median survival by DS-GPA was 2.2 months for Class 0-1.0, 5.3 months for Class 1.5-2.0, 10.6 months for Class 2.5-3.0, and 20.8 months for Class 4.0 (p < 0.001).
Results of the univariate analysis are shown in Table  2 . On univariate analysis, lower KPS score, the presence of extracranial disease, uncontrolled primary disease, lower DS-GPA, and larger total tumor volume all predicted worse overall survival. The number of brain metastases was not statistically significant when analyzed as a continuous variable (p = 0.082) whereas total tumor volume was (p = 0.031). There was no significant correlation observed between the number of treated lesions and the total tumor volume (Pearson correlation = 0.06, p = 0.34). On multivariate analysis, after adjusting for age, KPS score, extracranial disease, and the number of brain metastases, total tumor volume as a continuous variable was found to be a strong predictor for overall survival (Table 3) . Total tumor volume was also predictive of worse overall survival (p = 0.003) when analyzed with the DS-GPA score (which includes the number of metastatic lesions). When only patients who had a controlled primary disease and no extracranial disease were examined on multivariate analysis, larger tumor volume (p = 0.036), older age (p = , which was the most significant cutoff on univariate analysis and has been reported in previous studies, was also analyzed. A Kaplan-Meier plot for overall survival comparing total tumor volume (< 2 vs ≥ 2 cm 3 ; Fig. 1 upper) , showed statistically significant worse overall survival for patients with a total tumor volume ≥ 2 cm 3 (p = 0.008). On multivariate analysis, after adjusting for age, KPS score, extracranial disease, and the number of brain metastases, a tumor volume ≥ 2 cm 3 was found to be a strong predictor for worse overall survival (Table 4) .
Local Control and Distant Brain Failure
The 1-year actuarial local control rate of the treated lesions that had assessable follow-up imaging was 91.5%. Sixteen patients with a total of 18 lesions had documented local failure. These patients received salvage therapy, which consisted of surgery (n = 8), surgery combined with WBRT (n = 1), surgery combined with GKS (n = 1), repeat GKS (n = 2), WBRT (n = 2), and palliative measures (n = 4). Tumor volume as a continuous variable (p < 0.001) and a tumor volume ≥ 2.0 cm 3 (p < 0.001, Fig. 1 lower) were both predictive of worse local control on univariate analysis. Local tumor control at 1 year was 97% for lesions < 2 cm 3 compared with 75% for lesions ≥ 2 cm 3 (p < 0.001). This association was maintained on multivariate analysis (Table 5) . On univariate analysis, higher marginal dose was predictive of local tumor control (p = 0.018), but it was not a significant predictor on multivariate analysis (p = 0.94, Table 5 ). The actuarial 1-year distant brain failure rate was 64% and the median time to distant brain failure was 8 months. Treatment for distant brain failure included GKS (58%), WBRT (29%), and hospice/palliative care (13%). On multivariate analysis, tumor volume ≥ 2.0 cm 3 but not the number lesions were significant for distant brain failure (Table 6 ).
Discussion
In this retrospective study of 250 patients with brain metastases treated initially with GKS alone, an increasing tumor volume was found to be a strong predictor of worse outcome after adjusting for other known prognostic factors. Tumor volume analyzed as a continuous variable and as a cutoff volume (≥ 2 cm 3 ) were both significant for worse outcome. Patients who had a total tumor volume ≥ 2 cm 3 had worse overall survival and higher distant brain failure compared with patients with volumes < 2 cm 3 . In addition, a single tumor volume ≥ 2.0 cm 3 was also predictive of local tumor failure. Volume, but not the number of lesions, was also an independent predictor of survival when analyzed in the subset of patients with a controlled primary disease and no extracranial disease.
There are limited data examining the role of SRS for patients with multiple (4 or more) brain metastases. Randomized trials of SRS included patients with only 3-4 metastatic brain lesions. 1, 2, 9 The current National Comprehensive Cancer Network Guidelines (version 2.2012) therefore use a cutoff of > 3 lesions to recommend WBRT over SRS. The RTOG RPA does not include lesion number or tumor volume, and the DS-GPA takes into consideration the number of lesions but does not take into account tumor volume. 6, 15 Our results challenge the convention that the number of brain metastases is the best indicator of prognosis or whether WBRT should be added. We propose that tumor volume may be a more appropriate selection criterion for radiosurgery than the number of brain metastases. In our data, tumor volume was found to be a better than or as good a predictor of overall survival as the number of metastatic brain lesions. This implies that patients with multiple small lesions and small volume (small tumor burden) can be good candidates for SRS.
Our results corroborate the findings of several other studies that have shown that total tumor volume is an important prognostic factor. 4,10,11 Likhacheva and colleagues found a similar tumor volume of > 2 cm 3 to be predictive of worse overall survival, distant brain failure, and local control. In their multivariate model, overall survival, distant brain failure, and local control were not associated with the presence of 4 or more brain lesions. 11 Researchers at the University of Pittsburgh found a tumor volume < 3 cm 3 to be associated with better survival on multivariate analysis in a study of breast cancer patients. 10 Bhatnagar et al. examined patients with more than 4 brain metastases and found total treatment volume to be the strongest prognostic factor, and found that the number of lesions was not statistically significant. 4 There are also retrospective data demonstrating that SRS is an effective treatment option for patients with more than 5 brain metastases and in patients with more than 10 brain metastases. 7, 8 In patients with more than 10 lesions, Grandhi and colleagues found that in patients who died because of intracranial disease progression, the only significant prognostic factor associated with the duration of survival was total radiosurgery volume. 7 In our data set, volume as a continuous variable and a tumor volume ≥ 2 cm 3 were both associated with worse local control. This finding is consistent with results reported from MD Anderson 11 and the University of Pittsburgh, 4 which also found larger tumor volume to be associated with worse local control. These data support our view that tumor volume is a more significant prognostic factor than the number of brain metastases.
While randomized prospective data are missing for patients with more than 4 brain metastases, there is mounting evidence that treating with SRS and deferring WBRT is an acceptable approach in these patients. Currently, Japanese researchers are trying to determine what the optimal number of brain metastases is for SRS. The ongoing prospective multicenter trial JLGK0901 evaluates patients with 1-10 brain metastases undergoing GKS alone without WBRT. The study's objective is to prove noninferiority of overall survival in patients with 5-10 brain metastases compared with those with 2-4 brain metastases. 13 The number of lesions should not be the sole determinant of whether to treat a patient with SRS. The decision should be determined by a combination of multiple factors, including KPS score, age, status of extracranial disease, location of the tumor, number of metastatic lesions, and tumor volume. In fact, in our cohort, KPS score, age, and extracranial disease status were still the strongest prognostic factors. The DS-GPA is considered the most prognostic of the indices, but it does not include tumor volume. We propose that tumor volume should be incorporated into future prognostic models and randomized trials because it appears to be a stronger prognostic factor than number of metastases. While our study found a tumor volume cutoff of ≥ 2 cm 3 to be a very strong predictor of worse outcome, the appropriate tumor volume cutoff for predicting prognosis and local control will need to be further examined in large prospective controlled trials. There are limitations to our study, including its retrospective nature, which leads to loss of follow-up when analyzing local control and distant brain failure. However, survival is a concrete end point, and date of death or last follow-up date was known for all patients except 3 who were appropriately censored. The majority of our cohort is made up of patients with non-small cell lung carcinoma (NSCLC) and breast cancer, and that may mask the outcomes for other malignancies. Our data do not take into account the advancements in systemic therapy that can prolong survival. However, in the subset of patients who had a controlled primary disease and had no extracranial disease, tumor volume was still a significant and independent factor for overall survival. Finally, neurocognitive testing is important and was not performed on any of our patients. Neurocognitive testing is not routinely covered by insurance carriers but should be incorporated into all future prospective studies. 
Conclusions
In this retrospective study, after adjusting for multiple variables, total tumor volume was found to be a strong predictor for worse overall survival, whereas the number of brain metastases was not. A larger tumor volume was also a predictor for distant brain failure and worse local tumor control. Our results indicate that tumor volume may be a better predictor of disease burden than the number of brain metastases. Tumor volume therefore should be taken into consideration when treating patients with brain metastases and when designing future prospective studies and developing prognostic indices.
